Search details
1.
Preclinical and clinical activity of DZD1516, a full blood-brain barrier-penetrant, highly selective HER2 inhibitor.
Breast Cancer Res
; 25(1): 81, 2023 07 06.
Article
in English
| MEDLINE | ID: mdl-37415239
2.
Pathologic and molecular responses to neoadjuvant trastuzumab and/or lapatinib from a phase II randomized trial in HER2-positive breast cancer (TRIO-US B07).
Nat Commun
; 11(1): 5824, 2020 11 17.
Article
in English
| MEDLINE | ID: mdl-33203854
3.
Luminespib plus pemetrexed in patients with non-squamous non-small cell lung cancer.
Lung Cancer
; 135: 104-109, 2019 09.
Article
in English
| MEDLINE | ID: mdl-31446981
4.
Phase Ib/II single-arm trial evaluating the combination of everolimus, lapatinib and capecitabine for the treatment of HER2-positive breast cancer with brain metastases (TRIO-US B-09).
Ther Adv Med Oncol
; 10: 1758835918807339, 2018.
Article
in English
| MEDLINE | ID: mdl-30542377
5.
Phase II trial of everolimus in patients with refractory metastatic adenocarcinoma of the esophagus, gastroesophageal junction and stomach: possible role for predictive biomarkers.
Cancer Chemother Pharmacol
; 76(1): 61-7, 2015 Jul.
Article
in English
| MEDLINE | ID: mdl-25969130
Results
1 -
5
de 5
1
Next >
>>